agilon health Plunges On A Poor Prognosis (Rating Downgrade)
- I initially rated agilon health, inc. as a “hold” due to its volatile financial results and uncertain future, but recent developments necessitate a downgrade to 'sell'.
- The company's stock plummeted 60.1% since my last article, driven by disappointing Q3 results and reduced guidance, despite revenue growth.
- Rising medical costs and expansion expenses have severely impacted profitability, with a significant increase in net loss and negative EBITDA.
- Although agilon health has substantial cash reserves, the drastic downward revision in guidance and ongoing cost uncertainties undermine investor confidence.
MoMo Productions
Those who follow my work closely know that I have a pretty solid track record with my investment calls. But every so often, I, like anybody else, can make a mistake. Admitting to shortcomings is one of the most important things that
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
